EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Does botulinum neurotoxin A make walking easier in children with cerebral palsy? A randomized clinical trial

Siri Merete Brændvik iD, Anne Elisabeth Ross Raftemo, Karin Roeleveld, Guro Lillemoen Andersen, Kjersti Ramstad, Turid Follestad, Ånen Aarli, Marcin Bonikowski, Torstein Vik, Walking Easier

Developmental Medicine & Child Neurology · 2025

DOI: 10.1111/dmcn.16038 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Developmental Medicine & Child Neurology, 2025. Verfasst von Siri Merete Brændvik und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuromedicine and Movement Science, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, NTNU, Tron…. Hauptthemen laut MEDLINE: Cerebral Palsy, Botulinum Toxins, Type A, Walking, Neuromuscular Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Regional Health Authorities in Norway, Fakultet for medisin og helsevitenskap, Norges Teknisk-Naturvitenskapelige Universitet.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To assess the effect of single botulinum neurotoxin A (BoNT‐A) injections into the calf muscles on the gross energy cost of walking in children with cerebral palsy (CP) and to evaluate the effect of BoNT‐A on walking capacity, physical activity, perceived changes in mobility, and pain.

Method

This was an industry‐independent, randomized, quadruple‐blind, placebo‐controlled, multicentre trial ( ClinicalTrials.gov registration: NCT02546999). Sixty‐one children (33 male, median age [range] = 8 years [4–16 years]) with spastic CP and classified in Gross Motor Function Classification System (GMFCS) levels I and II allocated to single injections of either BoNT‐A or 0.9% saline into the calf muscles. The main outcome was gross energy cost (J/kg/m); secondary outcomes were walking capacity, habitual physical activity, perceived change in mobility tasks, and calf pain at baseline, 4 weeks (P1), 12 weeks (P2), and 24 weeks (P3) after the injection.

Results

The mean change in energy cost did not differ significantly between groups at the primary time point P2 (−0.27 J/kg/m, 95% confidence interval − 0.91 to 0.36, p = 0.404), nor at P1 or P3. Regarding the secondary outcomes, there was some evidence of a larger reduction in pain intensity in the group given BoNT‐A ( p = 0.043).

Interpretation

One treatment with BoNT‐A was not superior to placebo in making walking easier in children with CP classified in GMFCS levels I and II, at least in the short term. BoNT‐A may have a pain‐reducing effect.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cerebral PalsyBotulinum Toxins, Type AWalkingNeuromuscular AgentsHumansChildMaleFemaleAdolescentChild, PreschoolEnergy MetabolismTreatment OutcomeMuscle, Skeletal

Substanzen

Botulinum Toxins, Type ANeuromuscular Agents

Autor:innen und Institutionen

  • Department of Neuromedicine and Movement Science, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, NTNU, Trondheim, Norway.
  • Rehabilitation Clinic, St. Olavs University Hospital, Trondheim, Norway.
  • Vestfold Hospital Trust, Tønsberg, Norway.
  • Department of Laboratory Medicine, Children's and Women's Health, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, NTNU, Trondheim, Norway.
  • Oslo University Hospital, Oslo, Norway.
  • Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, NTNU, Trondheim, Norway.

ORCID-Profile: Siri Merete Brændvik

Förderung

  • Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology
  • Regional Health Authorities in Norway
  • Fakultet for medisin og helsevitenskap, Norges Teknisk-Naturvitenskapelige Universitet

Zitieren

APA

Brændvik, S. M., Ross Raftemo, A. E., Roeleveld, K., Andersen, G. L., Ramstad, K., Follestad, T., Aarli, Å., Bonikowski, M., Vik, T., & Walking Easier (2025). Does botulinum neurotoxin A make walking easier in children with cerebral palsy? A randomized clinical trial. Developmental Medicine & Child Neurology. https://doi.org/10.1111/dmcn.16038

Vancouver

Brændvik SM, Ross Raftemo AE, Roeleveld K, Andersen GL, Ramstad K, Follestad T, et al. Does botulinum neurotoxin A make walking easier in children with cerebral palsy? A randomized clinical trial. Developmental Medicine & Child Neurology. 2025. doi:10.1111/dmcn.16038

BibTeX
@article{Brndvik2025,
  author = {Brændvik, Siri Merete and Ross Raftemo, Anne Elisabeth and Roeleveld, Karin and Andersen, Guro Lillemoen and Ramstad, Kjersti and Follestad, Turid and Aarli, Ånen and Bonikowski, Marcin and Vik, Torstein and Walking Easier, Walking Easier},
  title = {Does botulinum neurotoxin A make walking easier in children with cerebral palsy? A randomized clinical trial},
  journal = {Developmental Medicine & Child Neurology},
  year = {2025},
  doi = {10.1111/dmcn.16038}
}
Kostenlos starten →